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expenditures ($11,538.8) than controls ($42,18.7, p < 0.0001).
Among the PsO patients, those with any psychiatric disorders had
a total health care expenditure of $18,046.70, as compared with
$10,503.50 for those without psychiatric disorders (p < 0.0001).
CONCLUSIONS: PsO patients have a signiﬁcantly higher preva-
lence of psychiatric disorders as compared with patients without
PsO. PsO patients with psychiatric disorders have signiﬁcantly
higher health care expenditure than those without such disorders.
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OBJECTIVES: To determine the proportion of cataract patients
requiring glasses at least 18 months after a bilateral implantation
of the ReSTOR(r) multifocal IOL, assess post-operative patient
satisfaction, and identify factors contributing to post-operative
eyeglass independence. METHODS: This cross-sectional study
was performed in France and Spain. Patients were selected at
random from medical charts of 10 centers. Medical data and
surgical procedure characteristics were collected retrospectively
from patient charts. A new speciﬁc scale, the Freedom from
Glasses Value Scale (FGVS) was administered to patients by
phone interview. FGVS scores range from 1 to 5, with 5 being the
most favourable score. A Bayesian network was constructed to
predict post-operative spectacle wear using FGVS items and
scores. RESULTS: A total of 304 patients with a mean age of
65.6 years were included. On average, the last eye surgery was
carried out 2.0 years before survey administration. Pre-
operatively, 62.5% of patients had a Snellen decimal distance
visual acuity superior to 0.8. Post-operative acuity was better
than 0.8 for 93.3% and 88.6% of the patients’ uncorrected near
and distance vision, respectively. Whereas 93.4% of patients
wore glasses before surgery, 87.2% were spectacle free after
surgery. Patients were very satisﬁed: 88% indicated that since
surgery their vision was better and 93% thought the surgery
produced a positive change. FGVS mean scores were: 3.81 and
3.80 respectively for practical and psychological advantages;
4.52 for evaluation of the result; 4.41 for feelings; and 4.47 for
global judgment. The Bayesian network demonstrated two con-
tributors to postoperative spectacle independence. Patients who
perceive considerable bother associated with wearing glasses,
and those sensitive to the opinions of others about their appear-
ance without glasses, are 3 times less likely to wear glasses
post-operatively. CONCLUSIONS:These study results conﬁrm
clinical trial ﬁndings. In actual medical practice over multiple
years, ReSTOR® IOL implantation provides both good distance
and near vision, a high level of spectacle independence, and high
patient satisfaction. Beyond good results from the lens, a desire
for spectacle freedom contributes to post-operative independence
from eyeglasses
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OBJECTIVES: The aim of this study was to compare vision 6
months after cataract surgery in patients implanted with one of
three IOLs: a monofocal or a multifocal (ReSTOR® or ARRAY-
SA40®). The latter two often free patients from spectacles for
near and distance vision. METHODS: A randomized clinical
trial comparing ARRAY-SA40® with a monofocal was pooled
with a prospective cohort of patients implanted with ReSTOR®.
Patient satisfaction, spectacle freedom rate, and corrected and
uncorrected, near and distance visual acuities (VA) were mea-
sured six months after surgery. Treatment group comparability
was checked at baseline. Imbalances on confounding factors
were adjusted using both linear models and propensity scores.
RESULTS: Sixtry-nine patients had a monofocal, 68 received the
ARRAY-SA40® and 83 were implanted with ReSTOR®.
ReSTOR® patients were younger (P < 0.0001) and had a lower
neuroticism score (P < 0.001). The sex-ratio was six females-
: four males. VA and spectacle dependency at baseline were com-
parable. At 6 months no difference was observed on distance VA,
corrected or uncorrected. Uncorrected near VA of ReSTOR®
patients was better (P < 0.0001) than with either a monofocal
IOL or ARRAY-SA40®. The probability of being free of spec-
tacles with ReSTOR was higher (P < 0.0001) than with a mono-
focal (RR = 10.2) or an ARRAY-SA40® (RR = 10.7). ReSTOR®
patients wearing spectacles never had multifocal glasses (the
most expensive), while 32% of ARRAY-SA40® and 52% of the
monofocal patients did. Good or excellent near vision satisfac-
tion with ReSTOR® was more often reported by patients than
with the ARRAY-SA40® or a monofocal (83.6%, 32.4%, 26.1%,
respectively; P < 0.0001). The corresponding satisfaction differ-
ence did not reach statistical signiﬁcance with distance vision
(82.1%, 75.0%, 67.7%, respectively; P < 0.17). Linear and pro-
pensity score adjustments did not modify the results. CONCLU-
SIONS: The uncorrected distance VA of the three IOLs was
similar. Near uncorrected VA in ReSTOR® patients was better
than in patients implanted with a monofocal or ARRAY-SA40®,
resulting in a higher spectacle independence rate and better near
vision patient satisfaction.
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OBJECTIVES: The aim of this study was to compare the one
year Nd:Yag laser incidence rate of two multifocal intra-ocular
lenses, ReSTOR® and Acrilisa®, implanted by a single surgeon
following his usual practices METHODS: This retrospective
study was based on all patients implanted with a ReSTOR® or
Acrilisa® multi-focal lens since the third trimester of 2004 at one
site. All patients with either cataract or clear lens were operated
by the same surgeon. Characteristics of the subjects, as well as
pre and post-op medical data were obtained from patient charts.
One year post surgical data were obtained from the surgeon’s
medical ﬁles and from other ophthalmologists, if any, involved in
post-surgical care. Time to Nd:Yag laser analysis was carried out
using Kaplan-Meier survival curves. Imbalance on confounding
variables was adjusted with a Cox model. RESULTS: Eighty
patients were bilaterally implanted with ReSTOR® and 76 with
Acrilisa®. Patients with ReSTOR® were more often male (52.5%
versus 30.7%; P < 0.001) and younger (63.1 versus 65.8;
P < 0.001). After one year of follow-up, 3.7% of the ReSTOR®
eyes had Nd:Yag laser versus 11.6% of the Acrilisa® eyes. Gender
was not found to be associated with Nd:Yag laser while older
patients were less prone to have capsulotomy (RR = 0.91,
IC95% [0.83–1.00], P = 0.05). Eyes with Acrilisa® had 3.54
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(IC95% [1.14–10.94]; P = 0.03) more chances to have Nd:Yag
laser than ReSTOR® eyes, after adjusting for age at surgery.
CONCLUSIONS:This analysis conducted at one year suggested
that following usual surgical practice in a private setting,
ReSTOR® eyes had signiﬁcantly less capsulotomy than those
implanted with Acrilisa®. Avoiding Nd:Yag laser and its potential
complications is important, especially in a young population.
Analyses at two and three years will be required to conﬁrm these
ﬁndings
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OBJECTIVES: To identify and characterize glaucoma patient
compliance proﬁles and to evaluate the impact on treatment
efﬁcacy. METHODS: A computerized device (Travalert®) that
collects daily instillation time and number of drops was given to
a cohort of patients for three months. A patient was declared
compliant when at least 2 drops per day were instilled, one in
each eye. Two compliance rates were calculated per week: during
the weekend and the remaining ‘working’ days. Principal com-
ponent analysis (PCA) was performed followed by an ascendant
hierarchical classiﬁcation (AHC) to identify groups of compliant
patients. Their characteristics were compared using chi-square or
ANOVA. RESULTS: A total of 113 patients were included (mean
age 66.5, 51.8% male), and 86.7% had primary open angle
glaucoma. Mean IOP was 24.2 mmHg before using Travalert®.
57.5% were treated with DuoTrav® and 42.5% with Travatan®.
PCA identiﬁed two axes (compliance intensity and week effect),
explaining 63.0% of the variance. AHC identiﬁed 3 compliance
groups: good (56.6% of the patients, compliance around 80%),
mild (21.2% of the patients, compliance around 50%) and poor
(22.1% of the patients, compliance around 20%). No predictive
variables (demographic or medical) of poor compliance were
identiﬁed. At the last visit, IOP was 16.1 mmHg on average and
statistically signiﬁcantly higher in the poor compliance group
(17.7 mmHg; P = 0.02). CONCLUSIONS: Compliance, mea-
sured objectively with a medical device, remains a major issue in
glaucoma treatment since about half the patients had compliance
lower than 80%. This impacted IOP control, a surrogate end-
point of glaucoma progression. None of the medical and demo-
graphics variables were associated with poor compliance
suggesting that forthcoming compliance research should identify
new targets (e.g. behavior) to identify patients beneﬁting from a
compliance training program.
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OBJECTIVES: To estimate the effectiveness of moxiﬂoxacin in
the treatment of bacterial conjunctivitis in adults using data
from the available randomized clinical trials METHODS: Four
randomized clinical trials were identiﬁed. Three compared
moxiﬂoxacin against placebo and one against oﬂoxacin. Effec-
tiveness parameters included early (day 3 to 5) and late (day 7
to 10) clinical efﬁcacy, late bacteriological efﬁcacy, and drop-out
due to lack of efﬁcacy. Fixed (Mantel-Haenzel) and random
(Der Simonian and Laird) effects models for risk ratios and risk
differences associated with treatment effects were estimated and
tests of homogeneity of effects across studies were done. All
analyses were conducted on the intention to treat population.
RESULTS: A total of 609 moxiﬂoxacin-treated patients and 606
placebo-treated patients were included in the meta-analysis.
Drop-out rates due to lack of efﬁcacy were consistently higher
for patients receiving placebo. However, there was signiﬁcant
heterogeneity in the estimates of drop-out rates for moxiﬂoxa-
cin and placebo groups across studies (p = 0.04). The probabil-
ity of both an early and a late clinical remission was higher with
moxiﬂoxacin (RR, 1.17, P = 0.001; RR, 1.13; P = 0.05, respec-
tively). The late bacteriological remission rate was about 25%
higher (RR, 1.26, P = 0.001) for patients treated with moxi-
ﬂoxacin. Eleven patients had to be treated with moxiﬂoxacin to
gain one additionanl clinical remission and 6 to gain one more
bacteriological remission. In comparison to oﬂoxacin, the prob-
ability of drop-out due to lack of efﬁcacy for the bacteriologi-
cally documented population was 2.63-fold lower (P = 0.03)
with moxiﬂoxacin; one extra failure could be avoided for every
19 patients treated. CONCLUSIONS: This meta-analysis sug-
gests higher clinical and bacteriological efﬁcacy of Moxiﬂoxacin
compared with placebo. The estimates reported here should be
interpreted with caution, given the small number of clinical
trials with published results. The lower proportion of drop-outs
for patients treated with moxiﬂoxacin compared with oﬂoxacin
suggests a lower use of rescue treatments for patients receiving
moxiﬂoxacin.
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OBJECTIVES: To compare the efﬁcacy of topical ocular
hypotensives for the treatment of intraocular hypertension and
glaucoma. Adverse events that may affect patients’ willingness to
comply with treatment were also assessed. METHODS: A sys-
tematic review was conducted to identify randomized controlled
trials in patients with glaucoma or ocular hypertension with a
prostaglandin analogue treatment arm. A total of 181 eligible
articles were identiﬁed with 73 suitable for meta-analysis. A
mixed treatment comparison (MTC) was performed to estimate
the relative efﬁcacy of the treatments. Studies connected to
latanoprost and reporting the mean and standard deviation in
absolute intraocular pressure (IOP) at three months were used in
the MTC since this maximised the analysis dataset. Baseline IOP
was included as a covariate in the MTC. Random effects models
were used, as study variance indicated some degree of heteroge-
neity. A second MTC was conducted to estimate the rate of
hyperaemia-type adverse events. RESULTS: The mean IOP at
three months for latanoprost is 17.42 mmHg from a baseline of
23.5 mmHg. Latanoprost is statistically signiﬁcantly better at
lowering IOP versus timolol, and latanoprost and timolol is
statistically signiﬁcantly more efﬁcacious versus latanoprost
alone. There were no further statistically signiﬁcant differences in
mean IOP for latanoprost versus any other treatments. The
hyperaemia event rate for latanoprost is 25.18%. Using the odds
ratio results compared to latanoprost, timolol has a statistically
signiﬁcantly lower event rate. Travoprost, bimatoprost, tra-
voprost and timolol, bimatoprost and timolol, latanoprost and
brimonidine, latanoprost and dorzolamide have statistically sig-
niﬁcantly higher event rates. CONCLUSIONS: The results indi-
cate that there is no clinically relevant difference in IOP lowering
between treatments except for timolol. However there are
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